• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Enhanced Memory NK Cell Development Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Memory NK Cell

Memory natural killer (NK) cells exhibit long-lasting immune memory capabilities, enabling them to respond more quickly and efficiently upon encountering a previously encountered pathogen or target. In the field of cancer treatment, memory NK cells show immense potential for enhancing immunotherapy outcomes. Several methods have been investigated to induce memory-like characteristics in NK cells in vitro. Among them, the method through the use of cytokines, including interleukin-12 (IL-12), interleukin-15 (IL-15), and interleukin-18 (IL-18), to induce memory-like characteristics in NK cells is becoming an increasingly researched and promising approach.

In combination with other immunotherapies, such as checkpoint inhibitors or CAR-T cell therapy, memory NK cells have the potential to significantly improve cancer treatment outcomes.

Fig.1 Memory NK cell-based immunotherapy.¹

Enhanced Memory NK Platform

Memory NK cells have shown great promise in augmenting the immune response against cancer cells. Creative Biolabs, a leading biotechnology company, is at the forefront of developing enhanced memory NK cells. Our innovative approach involves isolating and purifying NK cells from healthy donors and then inducing them into a memory phenotype through using cytokines, without the need for feeder cells. By carefully selecting and manipulating specific cytokines, we can efficiently induce and expand the population of memory NK cells, providing a valuable tool for studying their function and potential therapeutic applications. This process drives the NK cells into a highly activated functional state, enhancing their anti-cancer capabilities. Our team of experts meticulously tests and evaluates each batch of memory NK cells to ensure they meet the highest standards of quality and purity.

Memory NK cells Combined with CAR Platform

Moreover, Creative Biolabs also offers CAR-memory NK cell services through the integration of CAR structures into memory NK cells through genetic engineering. By equipping memory NK cells with CARs, which are synthetic receptors designed to recognize specific tumor antigens, we enable these cells to specifically target cancer cells with enhanced precision and efficiency. This tailored approach further enhances the therapeutic potential of Memory NK cells in cancer treatment, offering an exciting avenue for personalized immunotherapies that target and destroy malignancies.

Advantages of Our Services

• Expert guidance on cell culture conditions and cytokine dosages for maximal efficacy
• Comprehensive quality control measures to ensure the generation of potent memory NK cell populations
• Personalized approach to meet specific research goals and requirements
• Rapid turnaround time for efficient project completion
• Integration of latest research findings and developments in memory NK cell biology and CAR-NK research

Reference

1. Bakhtiyaridovvombaygi, Mehdi, et al. "Cytokine-Induced Memory-Like NK Cells: Emerging strategy for AML immunotherapy." Biomedicine & Pharmacotherapy 168 (2023): 115718.